Kidney International Reports · 2017 · 20 citations · 15 references
MedicineInternal MedicineNephrologyImmunopathologyMusculoskeletal InfectionRenal PathophysiologyCorticosteroid TherapyDiabetes MellitusImmune-mediated Renal DiseaseRenal DiseaseBone Fracture RiskComplications Of Corticosteroid TreatmentCorticosteroid RegimensCorticosteroid-induced OsteonecrosisInfection Risk FactorsInfection Risk With CorticosteroidsPrednisone UseSteroid-induced Osteonecrosis
IntroductionFew data are available on the risk of SAEs in corticosteroid users in IgAN populations. We describe the prevalence and risk factors of corticosteroid-related SAEs in a Chinese cohort.MethodsA total of 1034 IgAN patients were followed up in our renal center from 2003 to 2014. Prevalence of corticosteroid use and corticosteroid-related SAEs were noted. Logistic regression was used to search for risk factors of SAEs in corticosteroid users.ResultsOf the 369 patients with steroids therapy, 46 patients (12.5%) with 58 events suffered SAEs, whereas only 18 patients (2.7%) without corticosteroids suffered SAEs (OR: 5.45; 95% CI: 3.07–9.68; P < 0.001). SAEs included diabetes mellitus (n = 19, 5.1%), severe or fatal infection (n = 18, 4.9%), osteonecrosis of the femoral head or bone fracture (n = 6, 1.6%), cardiocerebral vascular disease (n = 4, 1.1%), cataract (n = 3, 0.8%), and gastrointestinal hemorrhage (n = 1, 0.3%). Multivariable logistic regression analysis revealed that advanced age (OR: 1.05; 95% CI: 1.02–1.07; P < 0.001) and hypertension (OR: 1.04; 95% CI: 1.01–1.06; P = 0.009) were risk factors for corticosteroid-related SAEs. Impaired kidney function (estimated GFR: OR: O.98; 95% CI: 0.96–0.99; P = 0.036) was a risk factor for severe infection. Accumulated dosages of corticosteroids were not identified as a risk factor of SAEs (OR: 1.09; 95% CI: 0.91–1.30; P = 0.365).DiscussionCorticosteroid use is associated with a high risk of SAEs in IgAN patients, especially those who are older, have hypertension, or impaired renal function. Current guidelines on corticosteroid regimens in IgAN should be reviewed with regard to safety.
15
Prevalence of Diabetes among Men and Women in China
Wenying Yang, Juming Lu, Jianping Weng et al. · New England Journal of Medicine · 2010 · 3.1K citations
The Commonest Glomerulonephritis in the World: IgA Nephropathy
Giuseppe D’Amico · QJM · 1987 · 871 citations
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
Thomas Rauen, Frank Eitner, Christina Fitzner et al. · New England Journal of Medicine · 2015 · 722 citations · Full text
Corticosteroids in IgA nephropathy: a randomised controlled trial
Claudio Pozzi, Piergiorgio Bolasco, Gianbattista Fogazzi et al. · The Lancet · 1999 · 528 citations
Corticosteroid Effectiveness in IgA Nephropathy
Claudio Pozzi, Simeone Andrulli, Lucia Del Vecchio et al. · Journal of the American Society of Nephrology · 2004 · 486 citations